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ABSTRACT
Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revisedIPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS).
Del(5q), –7/del(7q), +8 and –Y are among the most extensively studied cytogenetic abnormalities in MDS.
The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have
been reported in MDS, included but not limited to –X, 3q abnormalities, +13/del(13q), i(17q), +21/–21.
However, due to a very low number of patients, their impact on the prognosis of MDS is limited. Knowledge of
the molecular consequences of different cytogenetic abnormalities allows us to modify treatment regimens
based on drugs most active against the specific karyotype present, allowing for the opportunity to
individualize MDS treatment and improve patient care and prognosis.
Keywords: Cytogenetics, Karyotype, Myelodysplastic syndromes, Myelodysplasia, Chromosomal
abnormalities

INTRODUCTION
Myelodysplastic syndromes (MDS) are a group of
heterogeneous hematopoietic stem cell disorders
characterized by ineffective hematopoiesis, bone
marrow dysplasia and peripheral cytopenias with an
increased susceptibility in transformation to acute
myeloid leukemia (AML)1,2.The rapidly evolving
methods in molecular oncology and cellular biology
have provided insight into the molecular
pathogenesis of MDS, offering great advances in
diagnosis, gauging patient prognosis and treatment
response1.With modern developments in diagnostic
techniques, genetic abnormalities such as point
mutations and copy-number abnormalities can be
detected in a large number of MDS
patients3.Metaphase cytogenetics are capable of

identifying chromosomal abnormalities in up to 50%
of patients, though most abnormalities (up to 80%)
are detected via single-nucleotide polymorphism
(SNP) microarrays and/or array comparative
genomic hybridization (CGH) analysis nowadays3-5.
More than 50% cases of MDS exhibit somatic point
mutations that disrupt vital cellular processes,
including but not limited to DNA repair
mechanisms, signaling cascades, mRNA splicing and
epigenetic gene regulation2,6.These data have
expanded our understanding of MDS pathogenesis,
unravelling biological pathways that can be targeted
with novel agents and providing new developments
in the treatment of MDS. Different combinations of
chromosomal abnormalities and somatic point
mutations contribute to the large clinico-pathologic
spectrum of MDS7.
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Disease karyotype contributes to the International
Prognostic Scoring System (IPSS) score used in the
prognostication of MDS patients. Acquired
cytogenetic abnormalities are found in 40-50% of
cases with MDS and the clinical implications of each
individual karyotype play a crucial role in disease
course and management3, 5.
Identification of the specific genes affected by each
cytogenetic abnormality has been challenging and
the consequences of each abnormality are still
being elucidated7.Some of the common, as well as
rare cytogenetic abnormalities reported in MDS are
discussed here.
DEL(5Q)
Deletions of the long arm of chromosome 5 (5q) are
the most frequently found chromosomal
abnormalities in MDS (up to 15% of diagnosed
cases)3,8. MDS with del(5q) exhibits a
heterogeneous clinical picture, divided into two
large classifications based of clinico-pathology
features, responsiveness to therapy and patient
prognosis9.One subtype arises after prior exposure
to cytotoxic chemotherapy (mainly alkylating
agents) and/or radiation exposure and often shows
additional chromosomal abnormalities and TP53
mutations10-12.This subtype shows increased
likelihood of leukemic transformation and shorter
overall survival (ranging between 6-17 months,
depending on the number/severity of other
abnormalities)13.Conversely, patients with isolated
del(5q) have a relatively better prognosis and a
reduced risk of progression to AML (5–16% vs. 30–
45%)14. Patients with 5q– syndrome are included in
this subtype. Patients with multiple cytogenetic
abnormalities understandably follow an aggressive
disease course with substantially lower complete
response (CR) rates to lenalidomide in comparison
to those patients with isolated del(5q)
(approximately 3% vs. 67%)15. Importantly, specific
deletions in 5q chromosome also dictate prognosis.
For example, one study by Jerez et al.16
demonstrated that deletions involving the
centromeric and extreme telomeric regions of the
5q chromosome and/or specific genes (such as
MAML1andNPM1) are more likely to have
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additional chromosomal lesions and aggressive
disease course.
More studies have identified additional genes
affected by del(5q) and their contribution to the
complex pathophysiology of MDS. Loss-of-function
mutations in ribosomal protein S14 (RPS14 gene)
and several other genes encoding ribosomal
proteins are implicated in del(5q) MDS and
responsible for the characteristic erythroid
phenotype of 5q– syndrome17. The haploinsufficiency of these ribosomal proteins results in
impairment of pre-rRNA processing, ribosome
synthesis and selective induction of the p53
pathway in erythroid progenitors, halting cell-cycle
progression and arresting erythropoiesis18. Preclinical studies show that inactivation of p53
abrogates the cell-cycle arrest in the erythroid
progenitors, confirming the role of aberrant p53
induction in ineffective erythropoiesis in 5q–
syndrome19. Dysregulation of microRNA (miRNA)
has also been identified. miRNA-145 and miRNA146a in particular are localized to chromosome 5q
and are not expressed in del(5q) MDS progenitors.
A pre-clinical study by Starczynowski et
al.20identified that depletion of miRNA-145 and
miRNA-146a leads to upregulation of their targets,
identified Toll–interleukin-1 receptor domain–
containing adaptor protein (TIRAP) and tumor
necrosis factor receptor–associated factor-6
(TRAF6), resulting in inappropriate activation of
innate immune system pathways and signaling20.
These events lead to megakaryocytic dysplasia,
thrombocytosis, and neutropenia20. Another study
discussed the role of loss of APC gene, also located
on chromosome 5q, in the pathogenesis of MDS in
5q– syndrome21.
Lenalidomide is the FDA approved standard of care
for low-risk MDS with del(5q)22,capable of inducing
cytogenetic CR in 50-60% of patients with up to 70%
achieving transfusion independence23,24. However,
in some patients, a fraction of the del(5q) MDS
clone remains unaffected by lenalidomide and
persists despite CR, foreshadowing eventual disease
progression and relapse25. In addition, the subgroup
of patients harboring TP53 mutations with del(5q)
show relative resistance to lenalidomide and are
associated with short-lived treatment response11,12.
These observations highlight the importance of
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consolidating induction therapy as early as possible
after getting the patient in CR.
MONOSOMY 7, DEL(7Q)
Chromosome 7 anomalies (mainly monosomy 7 or
deletion of 7q) are reported in approximately 10%
cases of de novo MDS and up to 50% of therapyrelated MDS3,26. Chromosome 7 abnormalities
correlated with worse prognosis and reduced
overall survival in MDS and other myeloid
malignancies such as AML5. Commonly deleted
regions on 7q identified in MDS are located at
positions 7q22, 7q32-33, and 7q35-3627. A recent
study by McNerney et al.28 demonstrated that the
CUX1 gene (encoding a homeodomain protein) is
under-expressed in myeloid neoplasms with –
7/del(7q). Another recent study analyzing driver
mutations in MDS pathophysiology showed that
3.5% of patients harbored inactivating mutations of
the CUX1 gene29.CUX1 is thought to function as a
tumor suppressor gene in myeloid progenitor cells
by regulating the expression of proteins governing
the cell-cycle28, 29.
The
MLL5
gene,
encoding
a
histone
methyltransferase, is another gene mapped to
7q22. In the murine model, homozygous mutations
in MLL5 results in impaired neutrophil function and
erythropoiesis and a decreased repopulating
capacity of hematopoietic progenitors, even in the
presence of self-renewal stimuli30.Not only this, but
cells with mutated MLL5 alleles showed marked
sensitivity to demethylation-induced hematopoietic
differentiation30. These data indicate that MLL5
plays an important role in myeloid differentiation
(via DNA methylation) and warrants its investigation
as a predictor of response to hypomethylating
agents such as azacitidine in patients with MDS. It is
of note that although mutations in MLL5 have not
been found in myeloid neoplasia, reduced
expression of MLL5 does correlate with poor
prognosis in AML2. EZH2 is another chromatin
remodeler located on 7q36 and is mutated in
approximately 6% of MDS cases, correlating with
poor prognosis31. However, deletions in 7q do not
result in the loss of the EZH2 gene32.Chromosome
7q deletions are usually quite large and haploinsufficiency of multiple genes located in the
deleted regions contribute to MDS pathology7.

Cytogenetics in MDS

TRISOMY 8
Trisomy 8 is also a common cytogenetic
abnormality. Isolated trisomy 8 occurs in
approximately 5% of patients with MDS and
correlates with an intermediate prognostic risk
(median overall survivalof23 months)33. One
hallmark of +8 MDS is that the chromosomal
aberration is thought to occur late during disease
pathogenesis, as evidenced by its detection in
myeloid progenitors and near absence in CD34+
stem cells34.+8 MDS cells express high levels of antiapoptotic proteins (such as survivin) and exhibit
strong resistance to apoptotic stimuli (such as
gamma ray irradiation or withdrawal of growth
factors)35. Knockdown of these anti-apoptotic
proteins abolishes the survival advantage of the +8
MDS clone and represents a potential targeted
therapy that can be used in this subgroup of
patients35. In addition, +8 MDS patients show
remarkable response rates to immunosuppressive
therapies (up to 67%), indicating an underlying
autoimmune
pathophysiology
associated
specifically with trisomy 836.The overexpression of
anti-apoptotic proteins confers a survival advantage
to cells harboring the +8 karyotype over normal
hematopoietic progenitors, allowing the MDS clone
to survive the autoimmune microenvironment
while normal cells are destroyed as the MDS
phenotype develops.
Sex-chromosome abnormalities (–Y, –X)
Acquired loss of a sex-chromosome (–Y, in males, –X
in females) is an age-related phenomenon, but can
also occur in association with hematological
malignancies37.
MDS patients with isolated loss of the Y
chromosome are classified under the ‘very good’
prognosis group5. Ever since its first discovery in the
1960s, deletion of the Y chromosome and its
relationship with myeloid disorders has been under
scrutiny. Since loss of the Y chromosome has been
attributed to the normal aging process38 and the
fact that MDS incidence increases with age, the
association between –Y and MDS is unclear39.
Nonetheless, –Y is suggested to be a potential
driver in myeloid disorders as evidenced by the
pretreatment predominance of the 45, X, –Y
233
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karyotype followed by reappearance of normal
karyotype during remission from acute leukemia.40
Isolated loss of the Y chromosome is a frequent
cytogenetic finding in MDS37. A study in 2008
revealed that 14 of 142 patients (9.9%) with loss of
chromosome Y developed MDS and reported a 3.8fold increase in the risk of developing MDS with –
Y39.Trisomy 15 may also occur concurrently with –Y;
however, in the presence of trisomy 15, –Y appears
to be benign39. Further studies will help elucidate
the implications of simultaneous +15 and –Y.
On the other hand, loss of the X chromosome in
female patients is a relatively rarer defect (isolated
–X: 0.2-0.3% patients; –X in combination with other
chromosomal abnormalities: up to 1.5% patients)
and correlates with an intermediate prognosis
(approximately with a median overall survival of 16
months)5,41,42.Turner’s syndrome is defined by the
constitutional loss of the X chromosome; however,
patients with Turner’s syndrome do not seem to
have an increased risk of developing MDS and other
hematologic malignancies than the general
population43. Although –X is an easily detectable
finding on conventional cytogenetics, further
analysis such as phytohaemagglutinin-stimulated
lymphocytes
are
required
to
distinguish
constitutional loss of the X chromosome from an
acquired loss of the X chromosome restricted to
hematopoietic progenitors.44
3q abnormalities
3q abnormalities such as deletions, translocations
and inversions are rare occurrences in MDS but are
categorized as poor-risk features due to short
overall survival (median 20 months)3,5.Inv(3q) and
t(3;3)(q21;q26) usually affect the MECOM gene at
the 3q26 locus, leading to abnormal overexpression
of the EVI1 (a zinc-finger nuclear protein) which
results in uncontrolled proliferation and impaired
differentiation of hematopoietic progenitors45.
Chromosomal instability and interference with the
activity of transcription factors (such as PU.1,
GATA1 and RUNX1) are apparent mechanisms by
which EVI1 overexpression leads to the MDS
phenotype46-48.
A recent multicenter study highlighted the potential
of azacitidine as a specific therapy for MDS patients
with 3q lesions. With an overall response rate of
234
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50% (CR: 29%) and a median overall survival of 10.6
months, subgroup analysis also revealed that MDS
patients with 3q21 translocations had substantially
better response rates and overall survival49. In the
same study, patients with increased expression of
EVI1 without chromosome 3q lesions showed
comparable response to azacitidine49. Specific
therapy of MDS harboring 3q abnormalities can be
elucidated with further studies.
Trisomy 13, Del(13q)
Trisomy 13 is also an uncommon anomaly in MDS,
observed in about 0.2% of patients3,50,but is a
recurrent abnormality with increased occurrence in
AML (1-2% of cases)37. +13 usually presents with
advanced MDS with excess of blasts and moderate
to severe pancytopenia37, 50,hence categorized as a
poor-risk cytogenetic feature (approximate median
overall survival of 9.5 months)51.+13 shows a
propensity for older patients (usually >70 years of
age) and male predominance37,50.Since +13 is very
rare in MDS, most information regarding its clinical
implications and effects on prognosis is derived
from its appearance in AML patients. Trisomy 13
has shown a strong correlation between
abnormalities in the RUNX1 and FLT3 genes. Up to
87.5% of AML patients exhibiting the +13 karyotype
show cooperating mutations in the RUNX1 gene, a
transcription factor playing a vital role in
differentiation of hematopoietic progenitors into
mature blood cells52. Not only this, but +13 and
cooperating RUNX1 mutations are strongly
associated with abnormally high expression of FLT3
(up to 5-fold increased expression)53. In AML with
normal cytogenetics, FLT3 mutations are associated
with aggressive disease and poor prognosis54.
A report of two cases of AML harboring trisomy 13
showed that single-agent therapy with high-dose
lenalidomide was able to induce significant
response with durable cytogenetic and morphologic
CR55.Lenalidomide has already established a
prominent role in the treatment of del(5q) MDS and
may prove to be an attractive choice for +13
myeloid neoplasms (including MDS), which are
usually resistant to standard chemotherapy and
hypomethylating agents55.Keeping in mind the
overexpression of FLT3 in these patients, FLT3
inhibitors may also play a role as ‘individualized’
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therapy for +13 MDS56, though this needs to be
confirmed in clinical studies before its clinical
application.
Del(13q) not only occurs in a variety of hematologic
malignancies, mainly those of lymphoid cells
(chronic lymphocytic leukemia, multiple myeloma)
but also occurs in myeloid disorders37. In contrast to
trisomy 13, deletion of chromosome 3q occurs in
about 2% of MDS cases57.The RB1 gene, a tumorsuppressor gene involved in cell-cycle control and
cellular differentiation, is located in the deleted
regions of cells with del(13q)58.There is a strong
association between the occurrence of del(13q) and
therapy-related MDS and therapy-related AML,
foreshadowing poor outcomes in this patient
subgroup57, 59.
Trisomy 21, monosomy 21
Constitutional trisomy 21 is very well-known in the
context of Down’s syndrome and is associated with
an increased risk of AML and acute lymphoblastic
leukemia37.Besides being a hereditary disease, +21
may also occur as a clonal cytogenetic abnormality
in hematologic malignancies. Like +13 (discussed
above), +21 occurs much more frequently in AML
than in MDS60.+21 occurs between 0.3-0.8% of MDS
cases and is classified as one of the rare cytogenetic
abnormalities in the disease5,61. MDS patients with
trisomy 21 classically show low absolute neutrophil
counts with mild anemia and thrombocytopenia5.
There may also be an association with chronic
myelomonocytic leukemia.61The molecular events
that arise as a result of +21 are yet to be defined
and this represents an area of great interest for
future research. Currently, patients with isolated
+21 are classified in the intermediate-risk group,37
though some studies61 have reported that it could
be better fitted in the poor-risk group. Prospective
studies with large patient numbers will help classify
the risk magnitude and prognosis of these patients.
Monosomy 21 is also a rare cytogenetic finding in
MDS (isolated –21 in 0.3% cases and in combination
with other abnormalities in 0.5% cases)3,5. Like
trisomy 21, the impact of isolated monosomy 21 on
the prognosis of patients is limited due to
insufficient number of patients and studies and is
currently categorized under the intermediate-risk
group62. It should be noted that monosomy 21 on
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karyotype may be present as a technical artifact,
occurring randomly while cells are prepared for
chromosomal band analysis. Thus, the finding of –
21 on karyotype may not represent a true
monosomy and should be confirmed with additional
techniques such as fluorescence in situ
hybridization to avoid false positives63.
Isochromosome 17q
The i(17q) abnormality is classified under the
intermediate-risk category, occurring in about 1%
MDS cases as the sole abnormality64,65. MDS with
i(17q) has specific phenotypic features such as
profound anemia increased peripheral blood
leukocytes showing neutrophils with pseudoPelger–Huët anomaly and hyperplastic bone
marrow with micromegakaryocytic predominance64,
65
. The TP53 gene is located on 17p13.1 and while
one of the alleles is lost with the i(17q)
abnormality,65 the absence of mutations in the
remaining allele suggests that the loss of other
genes on chromosome 17p may play a role in the
unique pathogenesis of i(17q) hematologic
malignancies64. To further corroborate this
hypothesis, Fioretos et al.66 reported no
associations between the i(17q) and TP53
mutations. Recently, myeloid disorders (including
MDS) with i(17q) have been proposed to be a
distinct clinical entity, one with aggressive disease
biology, a higher likelihood of evolution to AML and
hence poor outcomes64.
Del(20q), del(12p), del(11q)
Patients with isolated del(12p) and del(20q) are
grouped under ‘good’-risk category based on the
cytogenetic classification. The outlook of these
patients is relatively favorable. Meanwhile, the
median overall survival was 6-9 years in patients
with isolated del (12p) and median survival in those
with isolated del (20q) was 5-6 years3, 8, 67. Patients
with isolated del(11q) have the most favorable
prognosis3,5. Although, del(20q) has been
extensively studied in the context of MDS, none of
the genes lost in the deleted regions of 20q have
shown association with the development of MDS,
indicating that an in-depth study of this cytogenetic
abnormalities is warranted to ascertain its role in
MDS pathogenesis3,5. Loss of the L3MBTL gene
235
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(which encodes one of the polycomb-group
proteins) in del(20q) is thought to lead to genomic
instability, but the L3MBTL gene may not be
mutated in MDS68. The ASXL1 gene regulates
epigenetic markers and gene expression by
interacting with polycomb-complex proteins,
various transcription activators and repressors. It is
located at the 20q11 locus, but falls outside the
deleted regions of the chromosome in del(20q). 2, 69
ASXL1 is mutated in 10-20% of MDS cases, and
corresponds with early evolution into AML and
shorter overall survival.69
Abnormalities in the ETV6 and CBL genes, located
on 12p13 and 11q23, respectively, are also reported
in MDS. ETV6encodes one of the ETS transcription
factors,70 whereas the product of CBL acts as a
negative regulator of activated receptor tyrosine
kinases71.
CONCLUSION
The broad heterogeneity of MDS highlights a large
variety of abnormalities that underlie disease
pathogenesis. Technological advancements have
enabled us to identify several new biological
abnormalities in patients with MDS and have
provided
profound
insights
into
MDS
pathophysiology. In some cases, unique genetic and
non-genetic aberrations are associated with specific
cytogenetic abnormalities and are responsive to
specific forms of therapy. Detailed characterization
of cytogenetic findings and the genes affected by
these anomalies will further improve our knowledge
of the cellular events that lead to MDS. With this
knowledge, treatment approaches can be
individualized for each patient, in part based on the
cytogenetic abnormalities harbored by the MDS
clone. This will not only yield better response rates
but will also reduce the toxicities associated with
other therapies that would be otherwise
‘suboptimal’ for a specific cytogenetic feature,
thereby improving patient quality of life and the
overall prognosis of MDS patients.
The rarer cytogenetic abnormalities have an unclear
impact on patient prognosis and are presently
categorized as intermediate-risk abnormalities and
most are not included in the current IPSS and the
revised-IPSS used in the prognostication of patients.
Emphasis should be placed on the collection of
236
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additional cases of rare cytogenetic abnormalities
to expand our knowledge of their impact and allow
for large studies to take place.
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